# TMS for OCD: FDA-Cleared Deep TMS Protocols and Response Rates Patients with Obsessive-Compulsive Disorder (OCD) who have completed an adequate course of selective serotonin reuptake inhibitor (SSRI) pharmacotherapy and a course of Exposure and Response Prevention (ERP) without sufficient relief frequently ask the same question: *what is left to try, short of surgery?* Since August 2018, the answer in U.S. outpatient psychiatry has included a Food and Drug Administration-cleared neuromodulation option — **Deep transcranial magnetic stimulation (Deep TMS)** delivered through a specialized H7 coil to the medial prefrontal cortex and anterior cingulate cortex. This article describes the device clearance, the pivotal trial that supported it, the protocol patients experience, the response rates the evidence base supports, and where Deep TMS fits in the treatment hierarchy for OCD. ## The headline answer In August 2018, the FDA cleared the BrainsWay Deep TMS System with the H7 coil for adjunctive treatment of adult OCD under 510(k) **K183303**.[^fda-k183303] This was the first non-pharmacologic, non-surgical neuromodulation device cleared in the United States for OCD. Standard "figure-8" rTMS systems cleared for major depressive disorder are not interchangeably cleared for OCD; the OCD indication is specific to the Deep TMS H-coil geometry and the prefrontal-cingulate target. "Cleared" rather than "approved" is the correct regulatory term — Deep TMS reached market through the FDA's 510(k) substantial-equivalence pathway, not the de novo approval pathway used for first-in-class drugs. ## What makes Deep TMS different from standard rTMS Standard rTMS for depression typically uses a **figure-8 coil**, which produces a focal magnetic field reaching roughly 1.5 cm beneath the scalp — sufficient to depolarize neurons in the dorsolateral prefrontal cortex but not deeper structures.[^perera-2016] Deep TMS uses the **Hesed coil (H-coil)** family, a multi-element coil design first described by Roth and Zangen, that distributes the magnetic field across a broader cortical area and reaches an effective depth of approximately 3 cm.[^roth-2007][^zangen-2005] The trade-off is intentional: a less focal but deeper field allows direct stimulation of circuits that figure-8 coils cannot reach without dose escalation that would exceed safety limits. For OCD, the relevant coil is the **H7** — engineered to stimulate the **medial prefrontal cortex (mPFC)** and **anterior cingulate cortex (ACC)** bilaterally. These regions are nodes of the **cortico-striato-thalamo-cortical (CSTC) circuit**, the neuroanatomical loop most consistently implicated in the pathophysiology of OCD across functional imaging, lesion, and deep brain stimulation evidence.[^greenberg-2010][^pauls-2014] CSTC hyperactivity correlates with the intrusion-and-compulsion cycle that defines OCD; the therapeutic hypothesis is that high-frequency stimulation of the mPFC/ACC nodes modulates this loop and reduces symptom severity. The H7 coil and the figure-8 coil are therefore not interchangeable hardware — they reflect different therapeutic targets and different device clearances. ## The pivotal trial: Carmi 2019 FDA clearance was supported by a multicenter, double-blind, sham-controlled randomized trial published in the *American Journal of Psychiatry* by Carmi and colleagues in 2019.[^carmi-2019] The trial enrolled 99 adults with treatment-resistant OCD across 11 centers and randomized them to active Deep TMS with the H7 coil or sham stimulation, delivered five days per week for six weeks. The primary outcome was change in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the standard severity measure for OCD. The findings were the basis for the clearance: - **Y-BOCS reduction** at six weeks was significantly greater in the active arm than in the sham arm (mean reduction of 6.0 vs. 3.3 points).[^carmi-2019] - **Response rate** (defined as ≥30% Y-BOCS reduction) was **approximately 38% in the active arm versus approximately 11% in sham** at the post-treatment assessment, and the active-arm advantage persisted at the one-month follow-up.[^carmi-2019] - Adverse events were dominated by headache during or after stimulation; no seizures occurred in the trial. An earlier proof-of-concept sham-controlled study by Carmi and colleagues (2018) had established the mPFC/ACC target and the symptom-provocation protocol used in the pivotal trial.[^carmi-2018] A terminology point matters here: the OCD field typically reports **response** (≥30% or ≥35% Y-BOCS reduction) rather than **remission**. Full Y-BOCS remission is a higher bar than full remission on depression scales, and OCD trials — Deep TMS included — show response-rate signals more reliably than remission-rate signals. The realistic clinical target is meaningful symptom reduction, not complete resolution. ## The protocol patients experience The Carmi 2019 protocol — and the protocol that defines the FDA-cleared regimen — has three components per session: 1. **Symptom provocation.** Immediately before stimulation, the patient briefly engages with their own obsessions or triggering content under clinician guidance, for approximately three to five minutes. The clinical rationale is that the CSTC circuit is most accessible to neuromodulation when it is actively engaged; provocation is intended to bring the relevant circuit "online" so the stimulation that follows has the greatest effect.[^carmi-2019][^carmi-2018] 2. **Deep TMS.** Approximately 18 minutes of stimulation at 20 Hz delivered through the H7 coil over the mPFC/ACC region, at an intensity set as a percentage of the patient's individualized motor threshold. 3. **Brief post-session debrief and clinical check-in.** Because the provocation step requires clinician time, **OCD Deep TMS sessions run roughly 30 minutes in the chair** — longer than the approximately 19-minute iTBS sessions used for depression. The standard course is **five sessions per week for six weeks (30 sessions total)**, with an optional continuation or taper at the treating psychiatrist's discretion based on response trajectory.[^carmi-2019] Like depression rTMS, the anti-OCD effects of Deep TMS depend on cumulative synaptic-plasticity changes that require closely spaced sessions; weekly or twice-weekly schedules are not the schedule on which the cleared evidence base was built. ## Where Deep TMS sits in the OCD treatment hierarchy The American Psychiatric Association practice guideline for OCD identifies two first-line treatments: **SSRIs at OCD-specific dosing** (typically higher than the dosing used for depression) and **Exposure and Response Prevention (ERP)**, the cognitive-behavioral psychotherapy with the strongest evidence base for OCD.[^apa-ocd] ERP is not interchangeable with generic cognitive behavioral therapy; the specific exposure-and-response-prevention mechanism is the active ingredient. A reasonable trigger for the Deep TMS conversation is the patient who has completed: - **Two or more adequate SSRI or SNRI trials** at therapeutic dose for at least 8 to 12 weeks each, including at least one trial at the higher doses commonly used in OCD; and - **A course of ERP** with a trained clinician, or a documented inability to engage in ERP due to symptom severity. Deep TMS is positioned as **additive to**, not a replacement for, ERP. Patients who have been unable to fully engage in ERP because the affective load of their obsessions is overwhelming sometimes find that the symptom-severity reduction from a course of Deep TMS makes the exposure work tolerable for the first time. Coordinated care between the prescribing psychiatrist and the ERP therapist is the standard of care during and after a Deep TMS course. Deep brain stimulation (DBS) — a surgical neuromodulation procedure with an FDA Humanitarian Device Exemption for severe, refractory OCD since 2009 — remains an option further down the treatment hierarchy for patients who have not responded to multiple medication trials, ERP, and Deep TMS. ## Insurance coverage realities Most major commercial payers and Medicare cover Deep TMS for OCD when payer-specific medical-necessity criteria are met. In practical terms, OCD coverage authorization has historically been **slower and more documentation-intensive** than coverage for major depressive disorder — typical commercial prior-authorization turnaround runs 5 to 15 business days; Medicare Advantage, Medicaid, and Federally-Facilitated Exchange QHPs operate under a 7-day standard / 72-hour expedited framework as of 2026.[^cms-0057-f] Carriers vary substantially in the documentation they require, particularly evidence of failed SSRI trials at OCD-specific doses and evidence of an adequate ERP attempt. The clinic's insurance team handles prior authorization and continued-treatment requests on the patient's behalf; patients can begin with an [insurance verification](/insurance/verify/) before any clinical scheduling commitment. Coverage for OCD typically authorizes the 30-session acute course; continuation sessions, if clinically indicated, require a separate authorization supported by Y-BOCS data and a letter of medical necessity. ## Key takeaways - **Deep TMS is FDA-cleared for adult OCD** under 510(k) K183303 (August 2018), delivered through the H7 coil to the medial prefrontal cortex and anterior cingulate cortex — nodes of the cortico-striato-thalamo-cortical (CSTC) circuit implicated in OCD. - The **Carmi 2019 pivotal trial** demonstrated significantly greater Y-BOCS reduction in the active arm than sham, with approximately **38% response (≥30% Y-BOCS reduction) versus approximately 11% sham**. - The protocol pairs **brief symptom provocation** before each session with **18 minutes of 20 Hz stimulation**, delivered **five days per week for six weeks (30 sessions)**; sessions run roughly 30 minutes in the chair. - Deep TMS is positioned as **additive to Exposure and Response Prevention (ERP)** and SSRI pharmacotherapy — not a replacement for either. The reasonable trigger for the conversation is two adequate SSRI trials and a course of ERP without sufficient response. - Most major commercial payers and Medicare cover Deep TMS for OCD with prior authorization; OCD coverage is typically more documentation-intensive than MDD coverage. ## Closing Patients in Anaheim, Orange County, and the broader 30-mile radius who have completed adequate SSRI pharmacotherapy and a course of ERP without sufficient relief from OCD symptoms can begin by reviewing whether the [OCD treatment pathway](/conditions/ocd/) at our clinic — coordinated care with the prescribing psychiatrist, the ERP therapist, and the [TMS therapy](/services/tms-therapy/) team — is the right next step. Most patients start with an [insurance verification](/insurance/verify/) so the coverage picture is clear before the clinical consultation that determines candidacy and protocol. ## Sources / Further reading [^fda-k183303]: U.S. Food and Drug Administration. 510(k) Premarket Notification K183303, BrainsWay Deep Transcranial Magnetic Stimulation System (BrainsWay Ltd.), cleared August 2018 for adjunctive treatment of adult patients suffering from Obsessive-Compulsive Disorder. [^carmi-2019]: Carmi L, Tendler A, Bystritsky A, et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. *American Journal of Psychiatry*. 2019;176(11):931–938. [^carmi-2018]: Carmi L, Alyagon U, Barnea-Ygael N, Zohar J, Dar R, Zangen A. Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD: clinical and electrophysiological outcomes. *Brain Stimulation*. 2018;11(1):158–165. [^roth-2007]: Roth Y, Amir A, Levkovitz Y, Zangen A. Three-dimensional distribution of the electric field induced in the brain by transcranial magnetic stimulation using figure-8 and deep H-coils. *Journal of Clinical Neurophysiology*. 2007;24(1):31–38. [^zangen-2005]: Zangen A, Roth Y, Voller B, Hallett M. Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil. *Clinical Neurophysiology*. 2005;116(4):775–779. [^greenberg-2010]: Greenberg BD, Rauch SL, Haber SN. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. *Neuropsychopharmacology*. 2010;35(1):317–336. [^pauls-2014]: Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. *Nature Reviews Neuroscience*. 2014;15(6):410–424. [^apa-ocd]: Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. *American Journal of Psychiatry*. 2007;164(7 Suppl):5–53. [^perera-2016]: Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. *Brain Stimulation*. 2016;9(3):336–346. [^cms-0057-f]: Centers for Medicare & Medicaid Services. Final Rule CMS-0057-F, *Advancing Interoperability and Improving Prior Authorization Processes*, effective 2026 — establishing 7-day standard and 72-hour expedited prior-authorization decision timeframes for Medicare Advantage, Medicaid, CHIP, and Federally-Facilitated Exchange QHP issuers.